These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8931810)

  • 21. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP; Saxena RK; Priyadarshy V
    J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment: expense of amphotericin B product.
    Andersen JM
    Ann Pharmacother; 1996 Nov; 30(11):1342. PubMed ID: 8913426
    [No Abstract]   [Full Text] [Related]  

  • 23. Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Clin Infect Dis; 2013 Dec; 57(12):1783-4. PubMed ID: 24140972
    [No Abstract]   [Full Text] [Related]  

  • 24. [Amphotericin B-intralipid 20% combination. In vivo evaluation of its tolerability].
    Débat Zoguéreh D; Poignard P; Sorriaux A; Brouqui P
    Ann Med Interne (Paris); 1997; 148(1):100-2. PubMed ID: 9137701
    [No Abstract]   [Full Text] [Related]  

  • 25. Minimizing nephrotoxicity using continuous infusion of deoxycholate amphotericin B.
    Gwee A; Cranswick N; Connell TG; Curtis N
    Pediatr Infect Dis J; 2014 Oct; 33(10):1098. PubMed ID: 25361191
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk factors for nephrotoxicity associated with conventional amphotericin B therapy.
    Girmenia C; Cimino G; Micozzi A; Gentile G; Martino P
    Am J Med; 2002 Sep; 113(4):351. PubMed ID: 12361831
    [No Abstract]   [Full Text] [Related]  

  • 27. Amphotericin B and cardiac toxicity--a case report.
    el-Dawlatly AA; Gomaa S; Takrouri MS; Seraj MA
    Middle East J Anaesthesiol; 1999 Feb; 15(1):107-12. PubMed ID: 10068976
    [No Abstract]   [Full Text] [Related]  

  • 28. Comments concerning 'The penetration of amphotericin B from an Intralipid formulation into fibrin loci in a rabbit model of candidiasis'.
    Washington C; Davis SS
    Biopharm Drug Dispos; 1995 Aug; 16(6):529-31. PubMed ID: 7579034
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.
    Nucci M; Loureiro M; Silveira F; Casali AR; Bouzas LF; Velasco E; Spector N; Pulcheri W
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1445-8. PubMed ID: 10348768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reply to Messori et al.
    Mistro S; Schooley RT; Badaro R
    Clin Infect Dis; 2013 Dec; 57(12):1784-5. PubMed ID: 24140973
    [No Abstract]   [Full Text] [Related]  

  • 31. Comment: compatibility of amphotericin B with lipid emulsions.
    Montoro JB; López RM; Pou L
    Ann Pharmacother; 1996 Dec; 30(12):1501. PubMed ID: 8968472
    [No Abstract]   [Full Text] [Related]  

  • 32. Toxicity of amphotericin B emulsion formulations.
    Washington C; Lance M; Davis SS
    J Antimicrob Chemother; 1993 May; 31(5):806-8. PubMed ID: 8380021
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful treatment of cryptococcal meningitis with liposomal amphotericin B (L-AMP-LRC-1) intolerant to conventional amphotericin B.
    Kirodian BG; Virani AR; Kshirsagar NA
    J Assoc Physicians India; 2002 Apr; 50():601-2. PubMed ID: 12164423
    [No Abstract]   [Full Text] [Related]  

  • 34. Liposomal amphotericin B for fever and neutropenia.
    Patel MA; Curtis K; Maguire JH
    N Engl J Med; 1999 Oct; 341(15):1153; author reply 1154-5. PubMed ID: 10515752
    [No Abstract]   [Full Text] [Related]  

  • 35. [Lipid derivatives of amphotericin B in treatment of systemic candidiasis].
    Rosenthal E
    Presse Med; 2000 Mar; 29(8):428. PubMed ID: 10738509
    [No Abstract]   [Full Text] [Related]  

  • 36. Is amphotericin B test dosing needed?
    Griswold MW; Briceland LL; Stein DS
    Ann Pharmacother; 1998 Apr; 32(4):475-7. PubMed ID: 9562144
    [No Abstract]   [Full Text] [Related]  

  • 37. Acrocyanosis developed with amphotericin B deoxycholate but not with amphotericin B lipid complex.
    Ozaras R; Yemisen M; Mete B; Mert A; Ozturk R; Tabak F
    Mycoses; 2007 May; 50(3):242. PubMed ID: 17472626
    [No Abstract]   [Full Text] [Related]  

  • 38. Reader clarifies the use of amphotericin B.
    Madej T
    Oncol Nurs Forum; 1998 May; 25(4):653. PubMed ID: 9599340
    [No Abstract]   [Full Text] [Related]  

  • 39. Nephrotoxicity of amphotericin B desoxycholate.
    Girmenia C; Gentile G; Micozzi A; Martino P
    Clin Infect Dis; 2001 Sep; 33(6):915-6. PubMed ID: 11512101
    [No Abstract]   [Full Text] [Related]  

  • 40. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?
    Lewis RE; Wiederhold NP
    Clin Infect Dis; 2003 Sep; 37(6):871-2. PubMed ID: 12955666
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.